Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot help with vaginal atrophy?
The O-Shot may be considered as part of a wider discussion for selected patients with symptoms associated with vaginal atrophy, but assessment is essential because low-oestrogen tissue change, vulval skin conditions, infections, pain, and urinary symptoms may need different or combined care.
Direct answer
The O-Shot may be considered as part of a wider discussion for selected patients with symptoms associated with vaginal atrophy, but assessment is essential because low-oestrogen tissue change, vulval skin conditions, infections, pain, and urinary symptoms may need different or combined care.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
Mechanism of Action
Utilizes autologous (patient's own) platelet-rich plasma containing growth factors (like PDGF, VEGF, TGF-β) to stimulate cellular repair.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Important safety note
Safety: The procedure is highly safe because it relies on 100% autologous material (your own blood), eliminating the risk of allergic reactions, foreign body rejection, or thermal burns.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
Growing Evidence Base: Recent studies, including systematic and scoping reviews, indicate that PRP significantly improves Vaginal Health Index (VHI) and Female Sexual Function Index (FSFI) scores in women with VVA/GSM.
Clinical context
Growing Evidence Base: Recent studies, including systematic and scoping reviews, indicate that PRP significantly improves Vaginal Health Index (VHI) and Female Sexual Function Index (FSFI) scores in women.
Evidence
Symptoms
Alternatives
What it means
Growing Evidence Base: Recent studies, including systematic and scoping reviews, indicate that PRP significantly improves Vaginal Health Index (VHI) and Female Sexual Function Index (FSFI) scores in women.
Why it happens
Symptoms may be linked to physical, hormonal, medication-related, psychological or relationship factors.
Evidence limits
Evidence may be developing, so the page should avoid promise-based language and explain uncertainty.
Treatment fit
Suitability depends on history, symptoms, examination where appropriate and discussion of alternatives.
What this means in practice
Preparation: Blood is drawn from the arm (usually 10-20 mL) using FDA/MHRA-cleared vacuum tubes containing an anticoagulant (like sodium citrate). Centrifugation: The blood is spun in a specialised centrifuge (e. g.
Procedure Duration: The entire process, from blood draw to injection, typically takes less than an hour (approximately 30 to 45 minutes). Onset of Results: Some patients report initial improvements in natural lubrication and sensitivity within the first 1 to 4 weeks.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
Growing Evidence Base: Recent studies, including systematic and scoping reviews, indicate that PRP significantly improves Vaginal Health Index (VHI) and Female Sexual Function Index (FSFI) scores in women.
It protects safety
Safety: The procedure is highly safe because it relies on 100% autologous material (your own blood), eliminating the risk of allergic reactions, foreign body rejection, or thermal burns.
It reviews alternatives
Preparation: Blood is drawn from the arm (usually 10-20 mL) using FDA/MHRA-cleared vacuum tubes containing an anticoagulant (like sodium citrate).
It sets expectations
Procedure Duration: The entire process, from blood draw to injection, typically takes less than an hour (approximately 30 to 45 minutes).
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Preparation: Blood is drawn from the arm (usually 10-20 mL) using FDA/MHRA-cleared vacuum tubes containing an anticoagulant (like sodium citrate). Centrifugation: The blood is spun in a specialised centrifuge (e. g.
Consultation priorities
Step 1: Consultation: A comprehensive medical review of symptoms (dryness, pain, incontinence), contraindications, hormone levels, and a discussion of realistic goals.
Consent
Aftercare
Follow-up
Before treatment
Step 1: Consultation: A comprehensive medical review of symptoms (dryness, pain, incontinence), contraindications, hormone levels, and a discussion of realistic goals.
During care
The clinician should explain the procedure, likely sensations, limits and alternatives.
Aftercare
Written aftercare and follow-up should be clear before the patient leaves.
When to reassess
If expected improvement does not occur, the plan should be reviewed rather than repeated automatically.
Practical expectations
Procedure Duration: The entire process, from blood draw to injection, typically takes less than an hour (approximately 30 to 45 minutes).
Costs, access and treatment plans should be confirmed before booking.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Atrophy is just dryness.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: PRP replaces menopause care.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: All postmenopausal discomfort is caused by atrophy.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Marketing language should not outrun clinical evidence.
Alternatives
Preparation: Blood is drawn from the arm (usually 10-20 mL) using FDA/MHRA-cleared vacuum tubes containing an anticoagulant (like sodium citrate).
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Safety: The procedure is highly safe because it relies on 100% autologous material (your own blood), eliminating the risk of allergic reactions, foreign body rejection, or thermal burns.
Are alternatives clear?
Preparation: Blood is drawn from the arm (usually 10-20 mL) using FDA/MHRA-cleared vacuum tubes containing an anticoagulant (like sodium citrate).
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Safety: The procedure is highly safe because it relies on 100% autologous material (your own blood), eliminating the risk of allergic reactions, foreign body rejection, or thermal burns.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Safety: The procedure is highly safe because it relies on 100% autologous material (your own blood), eliminating the risk of allergic reactions, foreign body rejection, or thermal burns.
Bleeding or discharge
Unexplained bleeding, unusual discharge or new pelvic symptoms should be reviewed.
Infection signs
Fever, spreading redness, pus or feeling unwell after a procedure needs urgent advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The best page is precise enough for a clinical searcher and accessible enough for someone newly hearing the term vaginal atrophy.
Clinical reality
- Growing Evidence Base: Recent studies, including systematic and scoping reviews, indicate that PRP significantly improves Vaginal Health Index (VHI) and Female Sexual Function Index (FSFI) scores in women with VVA/GSM.
Timeline and expectations
- Procedure Duration: The entire process, from blood draw to injection, typically takes less than an hour (approximately 30 to 45 minutes).
Practical logistics
- Preparation: Blood is drawn from the arm (usually 10-20 mL) using FDA/MHRA-cleared vacuum tubes containing an anticoagulant (like sodium citrate). Centrifugation: The blood is spun in a specialised centrifuge (e. g.
Research sources
- Chen, A. H. , et al. (2025). 'Platelet-Rich Plasma for Genitourinary Syndrome of Menopause in Breast Cancer Survivors.' Obstetrics & gynaecology, 146(5):728-736.
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 400 imported records. Additional reviewed material included UK clinical guidance, professional society guidance, peer-reviewed clinical papers, evidence reviews; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Vaginal Platelet-Rich Plasma (the O-Shot) for vulvovaginal atrophy is considered an off-label clinical application of FDA-cleared and MHRA-regulated medical devices. Individual results vary, and it is not a definitive treatment. Always consult with a licensed, qualified healthcare professional to determine if this procedure is medically appropriate for your specific health profile and symptoms. Results vary. Not a cure.
